ODC1 is a critical target of MYCN, and inhibition of ODC1 could impair the development of MYCN-amplified NB (29), implying that elucidating the aberrant activation of ODC1 will provide vital evidence for NB treatment. The gene discussed is MYCN; the disease is neuroblastoma.